期刊文献+

5-氨基水杨酸在Caco-2、L-MDR1和MRP2细胞中的转运研究 被引量:1

Study on transport of 5-aminosalicylate in Caco-2, L-MDR1 and MRP2 cell monolayers
下载PDF
导出
摘要 目的:研究5-氨基水杨酸(5-ASA)的跨膜转运是否涉及P-糖蛋白和多药耐药蛋白(MRP2)。方法:以Caco-2、L-MDR1、MRP2等三种细胞为模型,测定5-ASA跨膜转运的转运率和表观渗透常数。此外还研究了5-ASA对地高辛在Caco-2细胞转运的影响。结果:在Caco-2、L-MDR1和MRP2细胞,5、50、500gmol·L^-1 5-ASA从底端(B)→顶端(A)方向和A→B方向的转运率和表观渗透系数(Papp)均无统计学差异(P〉0.05)。在Caco-2细胞,与未用5-ASA组相比,各浓度5-ASA组(50μmol·L^-1~5mmol·L^-1)对地高辛的Papp和B→A方向的净转运率无明显影响(P〉0.05)。结论:5-ASA可能不是P-糖蛋白和MRP2的底物,也不能提示5-ASA是P-糖蛋白的抑制剂或诱导剂。 AIM: To investigate whether P-glycoprotein and MRP2 are involved in transport of 5-aminosalieylate ( 5-ASA ). METHODS: Permeability coefficients and transport rates of 5-ASA across Caco-2, L-MDR1 and MRP2 monolayers were measured. Trans epithelial transport of digoxin across Caco-2 monolayer with addition of 5-ASA was also studied. RESULTS: No differences of permeability coefficients and transport rates of 5-ASA at 5, 50 and 500 μmol·L^-1 between basal-to-apical and apical-to-basal direction were measurable across Caco-2, L-MDR1 and MRP2 monolayers ( P 〉 0.05 ). Compared with control experiments, no significant differences were observed in basal-to-apical net transport and Papp of digoxin (5 μmol·L^-1) in the presence of 5-ASA (50 μmol· L^-1 - 5 mmol·L^- 1 ) ( p 〉 0.05 ). CONCLUSION: 5-ASA can not be regarded as a substmte of P-gp or MRP2. Inhibition or induction of P-glycoprotein by 5- ASA could be excluded. Further studies are needed to identify the nature of the involved active carrier system(s) in intestinal secretion of 5-ASA.
出处 《中国临床药理学与治疗学》 CAS CSCD 2006年第11期1265-1269,共5页 Chinese Journal of Clinical Pharmacology and Therapeutics
基金 德国RobertBosch基金资助项目
关键词 5-氨基水杨酸 肠道转运 P-糖蛋白 细胞株 5-aminosalicylate intestinal transport P-glycoprotein cell lines
  • 相关文献

参考文献21

  • 1[1]Klotz U.The role of aminosalicylates at the beginning of the new millenium in the treatment of chronic inflammatory bowel disease[J].Eur J Clin Pharmacol,2000;56:353-62
  • 2[2]Sandborn WJ.Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis[J].Am J Gastroenterol,2002;97:2939-41
  • 3[3]Hanauer SB.Medical therapy for ulcerative colitis 2004[J].Gastroenterology,2004;126:1582-92
  • 4[4]Goebell H,Klotz U,Nehlsen B,Layer P.Oroileal transit of slow release 5-aminosalicylic acid[J].Gut,1993;34:669-75
  • 5[5]Layer PH,Goebell H,Keller J,Dignass A,Klotz U.Delivery and fate of oral mesalamine microgranules within the human small intestine[J].Gastroenterology,1995;108:1427-33
  • 6[6]Pauli-Magnus C,von Richter O,Burk O,Ziegler A,Mettang T,Eichelbaum M,et al.Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein[J].J Pharmacol Exp Ther,2000;293:376-82
  • 7[7]Artursson P,Karlsson J.Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells[J].Biochem Biophys Res Commun,1991;29:880-5
  • 8[8]Hidalgo IJ,Raub TJ,Borchardt RT.Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability[J].Gastroenterology,1989;96:736-49
  • 9[9]Frieri G,Pimpo MT,Andreoli A,Annese V,Comberlato M,Corrao G,et al.Prevention of postoperative recurrence of Crohn's disease requires adequate mucosal concentrations of mesalazine[J].Aliment Pharmacol Ther,1999;13:557-82
  • 10[10]Frieri G,Giacomelli G,Pimpo M,Palumbo G,Passacantando A,Pantaleoni G,et al.Mucosal 5-aminosalicylic acid concentrations inversely correlate with severity of colonic inflammation in patients with ulcerative colitis[J].Gut,2000;47:410-4

同被引文献11

  • 1Sudhakar Y, Kuotsu K, Bandyopadhyay AK. Buccal bioadhesive drug delivery---A promising option for orally less efficient drugs[J]. J Control Release, 2006, 114(1) : 15-40.
  • 2Senel S, Hincal AA. Drug permeation enhancement via buccal route: possibilities and limitations [ J]. J Control Release, 2001,72(1/2/3) : 133 - 144.
  • 3Matsuyama T, Morita T, Horikiri Y, et al. Influence of fillers in powder formulations containing N-acetyl-1-cysteine on nasal peptide absorption [ J ]. J Control Release, 2007,120(1/2) .88 - 94.
  • 4Sheshala RK. Development and validation of an HPLC-UV method for the determination of insulin in rat plasma: application to pharmaeokinetie study [ ] ]. Chromatographia, 2007,66(9/10) : 805 - 9.
  • 5Jacobsen J, Van Deurs B, Pedersen M, et al. TR146 cells grown on filters as a model for human buccal epithelium: I. Morphology, growth, barrier properties, and permeability[J]. Int J Pharm, 1995,125(2) : 165 - 184.
  • 6Nielsen HM, Rassing MR. TR146 cells grown on filters as a model of human buccal epithelium: IV. Permeability of water, mannitol, testosterone mad[ beta]-adrenoceptor antagonists. Comparison to human, monkey and porcine buccal mucosa[J]. Int J Pharm, 2000, 194(2):155- 167.
  • 7Morck Nielsen H, Romer Rassing M. TR146 cells grown on filters as a model of human buccal epithelium: V. Enzyme activity of the TR146 cell culture model, human buc- cal epithelium and porcine buccal epithelium, and permeability of leu-enkephalin[J]. Int J Pharm, 2000,200(2) : 261 - 270.
  • 8Whitehead K, Mitragotri S. Mechanistic analysis of chemical permeation enhancers for oral drug delivery [ J ]. Pharm Res, 2008,25(6) : 1412 - 1419.
  • 9Wang X, Zheng C, Wu Z, et al. Chitosan-NAC nanoparticles as a vehicle for nasal absorption enhancement of insulia[J]. J Biomed Mater Res B Appl Biomater, 2009,88 (1) : 150 - 161.
  • 10Nicolazzo JA, Reed BL, Finnin BC. Buccal penetration enhancers-how do they really work[J]? J Control Release, 2005,105(1/2) : 1 - 15.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部